Table 5.
Association of HDAC3 expression with various clinicopathological factors
| Characteristic | All cases | HDAC 3 low (IRS 0–4) | HDAC 3 intermediate (IRS 6–8) | HDAC 3 high (IRS 9–12) | P-value χ2-test for trends |
|---|---|---|---|---|---|
|
All cases |
224 (100%) |
80 (35.7%) |
73 (32.6%) |
71 (31.6%) |
-- |
|
Histological type |
|
|
|
|
0.34 |
| Ductal carcinoma/Other |
185 (100%) |
69 (37.2%) |
58 (31.4%) |
58 (31.4%) |
|
| Lobular carcinoma |
35 (100%) |
10 (28.6%) |
12 (34.3%) |
13 (37.1%) |
|
|
Histological grade |
|
|
|
|
<0.001* |
| G1 |
63 (100%) |
32 (50.8%) |
19 (30.2%) |
12 (19%) |
|
| G2 |
101 (100%) |
33 (32.7%) |
35 (34.6%) |
33 (32.7%) |
|
| G3 |
56 (100%) |
14 (25%) |
16 (28.6%) |
26 (46.4%) |
|
|
Nodal status |
|
|
|
|
0.61 |
| negative |
133 (100%) |
51 (38.3%) |
39 (29.3%) |
43 (32.4%) |
|
| positive |
78 (100%) |
26 (33.3%) |
26 (33.3%) |
26 (33.3%) |
|
|
pT-Stage |
|
|
|
|
0.55 |
| pT1 |
119 (100%) |
43 (36.1%) |
37 (31.1%) |
39 (32.8%) |
|
| pT2/pT3 |
87 (100%) |
28 (32.2%) |
29 (33.3%) |
30 (34.5%) |
|
| pT4 |
13 (100%) |
7 (53.8%) |
4 (30.8%) |
2 (15.4%) |
|
|
Hormone receptor status |
|
|
|
|
0.04* |
| Hormone receptor positive |
176 (100%) |
65 (36.9%) |
63 (35.8%) |
48 (27.3%) |
|
| Hormone receptor negative |
43 (100%) |
14 (32.6%) |
7 (16.3%) |
22 (51.2%) |
|
|
HER2 status |
|
|
|
|
0.12 |
| negative |
191 (100%) |
71 (37.2%) |
63 (35.8%) |
48 (27.3%) |
|
| positive | 25 (100%) | 8 (32%) | 4 (16%) | 13 (52%) |